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The receptor for macropbage colony stimulating factor (CSF-1),  the c-f  ms gene product, is a 
key determinant in the differentiation of monocytic phagocytes. Dissection of the human and 
mouse c-frns  proximal promoters revealed opposing roles  for nuclear  protooncogenes in the 
transcriptional regulation of this gene. On the one hand, c-ets-I, c-ets-2,  and the macrophage- 
specific factor PU.1, but not the ets-factor  PEA3, trans-activated the c-f  ms proximal promoter. 
On the other hand c-myb repressed proximal promoter activity in macrophages and blocked the 
action of c-ets-1  and c-ets-2.  Basal c-f  ms promoter activity was almost undetectable in the M1 
leukaemia line, which expressed high levels of c-myb, but was activated  as cells differentiated 
in response to leukemia inhibitory factor and expressed c-f  ms mRNA. The repressor  function 
of c-myb depended on the COOH-terminal domain of the protein. We propose that ets-factors 
are necessary for the tissue-restricted expression of c-f  ms and that c-myb acts to ensure correct 
temporal expression  of c-f  ms during myeloid differentiation. 
T 
he CSF-1 receptor is encoded by the c-f  ms protooncogene 
and is required for the growth, differentiation, and sur- 
vival of cells in the monocyte/macrophage lineage (1). The 
human c-f  ms gene is located on chromosome 5 in a tandem 
array with the platelet-derived growth factor receptor gene 
(2). c-f  ms is expressed in monocyte/macrophages and their 
committed precursors  and in placental trophoblasts (1, 3). 
Two distinct promoters appear to be at least partly respon- 
sible for the tissue-specific expression of the human gene (3). 
The placental promoter is located in the 3' region of the 
platelet-derived growth factor receptor adjacent to noncoding 
exon 1 of c-fins, whereas the monocyte-specific promoter is 
located in the segment ofintron 1 adjacent to exon 2, which 
contains the start codon (3). In contrast to the tissue-restricted 
activity of the human promoter, the mouse proximal pro- 
moter was demonstrated to be active in a wide variety of 
mouse cell lines (4). The effects of sequences in intron 2 (the 
first intron transcribed in macrophages) and the detection of 
incomplete transcripts  suggested that an attenuation/elonga- 
tion mechanism was responsible for directing tissue-specific 
expression  of the gene (4). 
The ets family of transcription factors contain a conserved 
DNA binding domain in the COOH-terminal region of the 
protein products and recognize a common purine-rich con- 
sensus sequence (5, 6). Ets factors act at enhancer elements 
in combination  with AP-1 family members to direct oncogene- 
responsive gene expression (7, 8). The ets-factors c-ets-1 and 
PU.1 mediate tissue-specific expression of genes in hemato- 
poietic cell types (9-12), in combination with other tran- 
scription factors such as the immunoglobulin-enhancer  binding 
factor NF-EM5 (13). PU.1 and c-ets-2 can both trans-activate 
the murine c-f  ms promoter in nonmacrophages. In macro- 
phages, which already express PU.1,  overexpression of this 
factor was repressive whereas c-ets-2  was stimulatory (14). 
Similar  studies of the human promoter identified a PU.1- 
responsive element around 170 bp upstream from the start 
codon that activated transcription in nonmacrophages and 
was essential for maximal expression in macrophages (15). 
The c-myb gene also encodes a DNA binding protein that 
acts as a transcriptional activator (16-20). The c-myb product 
is expressed primarily in hematopoietic cells (21) and is es- 
sential for the normal differentiation. A homozygous null 
mutation of this gene in transgenic mice resulted in the loss 
of hematopoietic precursors and embryonic lethality (22). The 
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and exogenous expression of myb blocks the differentiation 
of hematopoietic cell lines (25-27). Only a few actual targets 
of c-myb are known,  including mira-1  (28),  a promyeloid- 
specific gene of unknown function,  and the enhancers for 
the CD4 gene, the cdc2 gene, and the T cell receptor/$ chain 
(29-31).  In all of these cases,  c-myb  is a positive regulator 
of gene expression.  Activation of the mim-1  promoter by 
c-myb.has been reported to depend on interactions between 
c-myb and ets factors (32) and more recently between c-myb 
and CAAT/enhancer-binding factors (33, 34). Similarly, in- 
teraction between c-myb and the T cell factor CBF is critical 
for cell-specific activation of the/~ chain enhancer  (31). 
In the present work, we studied the elements contributing 
to the tissue-specific  use of the human and murine c-f  ms prox- 
imal promoters, focusing on the role of ets-factors and of c-myb. 
A  combination of transient transfection assays and in vitro 
protein binding assays demonstrated that ets-related factors, 
including c-ets-1,  c-ets-2,  and PU.1, may contribute as posi- 
tive factors to the tissue-specific potential of the c-f  ms pro- 
moter. The c-myb product also recognized sequences in the 
c-fins proximal promoter, but this interaction caused a cell- 
specific negative regulation of the promoter.  The COOH- 
terminal regulatory domain of c-myb was required for this 
negative regulation of the c-f  ms proximal promoter,  c-f  ms 
is identified as a potential target for the effects of c-myb on 
myeloid differentiation. 
Materials  and  Methods 
Cell Culture.  NIH 3T3 fibroblasts and COS-7 cells were cul- 
tured in Dulbecco's modified Eagles medium (high glucose formu- 
lation)  supplemented  with 10% FCS, 9.5 mM t-glutamine, and 
100 #g/ml mezlocillin, and growth in 5% CO2 at 37~  The mu- 
fine macrophage  cell lines RAW264 (35),  the myeloid leukemia 
M1, and the erythroleukemia cell line K562 (all obtained from Amer- 
ican Type Culture Collection, Rockville, MD) were grown in RPMI 
medium containing 9.5 mM t-glutamine and 5 or 10% FCS (the 
former for K562). 
Reporter and Expression Plasmids.  The CSFR-5000 plasmid was 
constructed by placing the proximal human CSF-1R promoter frag- 
ment that contained 5 kb of sequences upstream of the initiation 
codon 5' to a luciferase  reporter gene (8, 20). The CSFR-900 reporter 
contained a proximal promoter fragment truncated by HindlII diges- 
tion, whereas  the CSFR-430 and CSFR.-367 plasmids were con- 
structed using PCR fragments corresponding to -430 to +1, or 
-367 to + 1, respectively, of the proximal CSF-1R promoter. The 
primers used for PCR were 5'-GGGGATCCGGGATCTGCCAGA- 
G-3' and 5'-GGGGATCCGCTGCTCTTGGACA-3' for 5' ends, 
respectively, and 5'-GGAGATC~CTCGG~A-Y  for the 
3' end. After cloning, these PCIL fragments were sequenced to en- 
sure that mutations were not introduced by the PCR amplification. 
All of these promoter fragments were placed in luciferase reporters 
in either Bluescript (Promega Biotech, Madison, WI), or PBR322 
vectors. The results presented here were obtained with the Bluescript 
vectors, but data with both vectors were identical. This result renders 
unlikely the prospect that vector sequences contributed to the regu- 
lation observed.  The murein c-f  ms promoter constructs, pGL2- 
3.Sfms and pGL2-O.3fras, were produced as described previously (4). 
The ets-related purine-rich sites located beginning at position 
-  151 were altered in the CSFR-430 reporter by PCR site-directed 
mutagenesis (8) using the oligonucleotide (sense strand) 5'-GCC- 
CAAGTAGTAGTAAGAGTAAAACAAG-3' and its complement 
along with the oligonudeotides that define the boundaries of the 
CSFR-430  construct described above. 
The myb-expression vectors contained the long terminal repeat 
promoter of Rous sarcoma virus and an intron-polyA processing 
site derived from SV40 (20). The COOH-terminal truncated c-myb 
contained amino acids 1-437,  thus deleting the COOH-terminal 
199 amino acid residues of the full-length protein (36, 37). The 
expression vector for c-ets-2 and PEA3 (38) was a cytomegalovirus 
immediate early promoter-based vector that contained the influenza 
hemaglutinin epitope  tag  recognized  by monoclonal antibody 
12CA5-F (39).  The SV40 early promoter c-ets-I vector encoded 
the 54-kD gene product, and was a gift from Jaques Ghysdael (In- 
stitut Curie, Orsay, France). SV40-based expression plasmids for 
routine c-ets-2 and PU.1 (ets-2 pECE and PU-pECE) were a gift 
from Dr. Richard Maki (La Jolla Cancer Research Foundation; La 
Jolla,  CA). 
Transfection Assays.  NIH 3T3 cells were transfected either by 
the calcium phosphate method (8) or by electroporation  (40). In 
some experiments  a plasmid encoding the secreted alkaline phos- 
phatase gene was included as an internal control (8). For the cal- 
cium phosphate method, 3 #g of reporter were included per ex- 
periment, whereas the amount of expression vector for the ets-rehted 
or myb-derived proteins  was 0.25 #g, determined empirically as 
optimal. The RAW264, M1, and K562 cells were transfected by 
electroporation as described (40). The amount of plasmid used for 
the electroporation experiments is recorded in the individual figure 
legends. Luciferase and secreted alkaline phosphatase reporters were 
assayed as described (8, 20). All transfection experiments reported 
were performed a minimum of three times in duplicate  with at 
least two different preparations  of plasmid  DNA. 
COS-7 cells were transfected by the calcium phosphate method 
using 15/~g of expression vector per dish for c-ets-2 or c-myb. The 
whole cell extracts were prepared 48 h after transfection as described 
(41). Overexpression of the protein was confirmed by Western blot- 
ting using the monoclonal antibody 12CA5-F (data not shown). 
Preparation of Nuclear Extracts and Mobility Shift Assays.  Prepa- 
ration of nuclear extracts from RAW 264 or NIH 3T3 cells and 
electrophoretic  mobility shift assays (EMSA)  l were accomplished 
exactly as described earlier (8, 14). The double-strand  oligonucleo- 
tides based upon the  -150 human c-fras element was 5'-GCC- 
CAAGGAGGAGGAAGAGGAAAACAAG-3'  (sense strand). The 
sequence of the mutated oligonucleotide for the ets-binding ex- 
periments was identical to that used for site-directed mutagenesis 
(see above). The SV40 PU-box sequence used in EMSA was 5'CTG- 
AAA CAGGAACTTGGTTAGGTA-Y.  In the antibody supershift 
assays, the whole-cell extract from COS-7 cells (see above) was in- 
cubated for 10 rain at room temperature with the antibody before 
adding the probe. Recombinant PU.1 was produced in Escherichia 
coli as described previously  (14). 
RNA  Preparation and  Northern  Analysis.  M1  cells (1-2  x 
106/ml) were cultivated in medium with or without leukemia in- 
hibitory factor (LIF) (ESGRO; AMRAD, Melbourne, Australia) 
at a concentration of 1,000 U/ml. Each day the culture was split 
in half by removal of cells and addition of fresh medium. The har- 
vested cells, plus or minus LIF, were used to prepare total RNA. 
Extraction, Northern blotting, and cDNA hybridization were car- 
ried out as described previously  (42). 
1 Abbreviations used in this paper: EMSA, electrophoretic mobility shift 
assay; LIF, leukemia inhibitory  factor; RSV-SEAP, tLous Sarcoma 
virus-secreted alkaline phosphatase; TK, thymidine kinase. 
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The c-f  ms Promoter Is More Active in Macrophage  Cell Lines 
Than  in  Other Cell  Types.  Previous studies of the human 
c-f  ms promoter present in the first intron of the gene indi- 
cated that it displayed myeloid/macrophage specificity, but 
the interpretation was complicated by the inclusion of the 
SV40 enhancer in the reporter construct (3). To examine the 
activity of the proximal promoter in the absence of exoge- 
nous enhancers, 5 kb of the human c-f  ms proximal promoter 
adjacent to exon 2 was tested in transient assays using lu- 
ciferase reporters. The activity of the 5-kb promoter frag- 
ment was assayed and compared with the herpes simplex virus 
thymidine kinase (TK) promoter in the mouse macrophage 
cell line RAW264, the human erythroleukemia cell line K562, 
or in NIH 3T3 fibroblasts.  Results are shown in Table  1. 
In either NIH 3T3 or K562 cells,  the TK promoter was 
markedly more active (10-fold) than the c-f  ms proximal pro- 
moter. In contrast, the c-f  ms proximal promoter was 10-fold 
more active than TK in the macrophage cell line. These results 
indicate an approximate 100-fold difference in c-f  ms promoter 
activity in RAW264 cells versus the other two cdl types rel- 
ative to the TK promoter. The activity of the c-f  ms proximal 
promoter was also compared with the strong human B-actin 
promoter with the same result; it had 50-100 times the rela- 
tive activity in RAW264 cells than in either of the two non- 
macrophage cell lines (data not shown). 
A  series of 5' c-f  ms human promoter deletions was con- 
structed and tested in these cell lines. Results obtained with 
two informative 5' deletions are represented in Table 1. When 
tested in RAW264 cells, the c-f  ms proximal promoter activity 
slightly decreased with progressive ddetion of 5' sequences. 
A 430-bp fragment still retained 25-50%  of wild-type ac- 
tivity and was sixfold more active than the TK promoter. 
In K562 or NIH 3T3 cells, progressive 5' deletion of the prox- 
imal promoter raised the activity relative to the larger pro- 
moter constructs as well as to the TK promoter. The same 
results were obtained in two different luciferase reporter vectors 
(see Materials and Methods), indicating that the increased 
activity is c-f  ms promoter-specific, and not dependent on vector 
sequences.  Thus, while the 430-bp proximal promoter still 
displayed macrophage-specificity, the effect was diminished 
from 100-fold  (see above) to 10-20-fold relative to the TK 
promoter. 
The apparent tissue specificity of the human promoter is 
not consistent with earlier work on the mouse promoter, 
wherein no distinction could be made between RAW264 cells 
and a series of murine tumor cell lines, including L929 fibrosar- 
coma, Lewis lung carcinoma and MOPC31C B cell lymphoma 
(4).  Accordingly, a comparison of the mouse and human 
promoters was carried out in NIH 3T3 cells and RAW264 
cells. The 3.5-kb mouse c-f  ms promoter was approximately 
five times more active than the 5-kb human promoter in both 
cell types. Nevertheless, there was the same apparent tissue- 
specificity in comparison with the TK promoter (Fig.  1) ar- 
guing that there is no fundamental difference between the 
mouse and human genes. The relatively high activity of the 
murine c-f  ms promoter in macrophages has been confirmed 
in WR19M and PU5/1.8 murine macrophage cell lines (our 
unpublished observations) and parallels  studies of Zhang et 
al.  (15) of the human promoter in human cell lines. 
To identify critical c/s-acting elements of the c-f  ms pro- 
moters, we concentrated on sequences located more prox- 
imal to the gene which appear critical for expression in both 
the mouse and human genes.  An alignment of the mouse 
and human promoters is presented in Fig. 2 A. The number 
is indicated relative to the start codon, because in both spe- 
cies there are multiple transcription start sites. Two types of 
consensus sequences present in this region of the promoter 
were the focus for the studies presented below. In light of 
earlier findings showing that c-ets-2 and PU.1 can trans-activate 
the mouse promoter (14) one focus of interest was purine- 
rich ets-like binding sites. Both mouse and human promoters 
contain multiple repeats of sequences containing the ets core. 
It is difficult to choose an optimal alignment of the mouse 
and human proximal promoters containing these sequences, 
Table  1.  CSF-1R Promoter Activity  in Macrophage vs.  Non-macrophage Cell  Types 
Promoter 
Cell line  CSFR-5000  CSFR-900  CSFR-430  TK 
RAW  264  36.3  (2.5)*  29.7  (2.5)  18  (2.2)  2.9  (0.14) 
Ratio:  TK  12.5'  10.2  6.2  1 
K562  32.7  (8.7)  45.3  (17.6)  109.3  (17.9)  314.7  (96.3) 
Ratio:  TK  0.10  0.14  0.35  1 
NIH  3T3  0.93  (0.53)  0.67  (0.21)  4.8  (1.2)  12.4  (1.05) 
Ratio:  TK  0.08  0.05  0.38  1 
* Relative luciferase activity of each of the promoter reporters in the indicated cell lines. Each value is the average of three independent experiments 
performed in duplicate. The numbers in parentheses  are the SD. 
Ratio of the relative luciferase activity of the CSF-1R promoter constructs to the TK promoter in the respective  cell line. 
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Fig,re  1.  Comparison of the activities of the mouse and human c-f  ms 
promoters in RAW264 and NIH 3T3 cells. Cells were transfected by elec-  -160  M 
troporation (Materials and Methods) with 10/~g of either pGL2-3.Sfms  -18o  H 
(mouse 3.5 kb flanking sequence), pCSFR-5000  (human 5.0 kb flanking 
sequence), or pTK-ludferase (control).  After  24 h, cells were harvested  -120  M 
and assayed for luciferase activity as described. Results are the average of  -13o  H 
three independent experiments  +_  SD. 
since the mouse contains two apparent  insertions relative  to 
the human sequence, a GT repeat and a string of As. Atten- 
tion has been focused for the purpose of this study on a con- 
served purine-rich region around  -150  in the human and 
-130 in the mouse relative to the start codon (Fig.  2 A). 
This is downstream of the site studied by Zhang et al.  (15) 
around  -170 in the human (Fig. 2 A). The  -170 site does 
not appear  to be conserved in the mouse (Fig.  2 A). 
Binding sites for the transcription factor c-myb were the 
second focus of interest. A perfect  c-myb consensus binding 
site is identified in the human promoter around  -375 rela- 
tive to the start codon (Fig. 2 A), and we have demonstrated 
that this sequence is recognized by recombinant c-myb (data 
not  shown).  Based  upon  the  detailed  binding  studies  of 
Tanikawa et al. (43) the consensus core binding site for myb 
is AaCnGnH but maximal binding requires  a 16-18 bp se- 
quence.  Earlier  studies by Sakura et al.  (44) identified low 
affinity myb sites (MBSII) in the SV40 early promoter. These 
sites had single bp mismatches within the core sequence but 
additional matches in sequences flanking the core. Muhimers 
of MBSII were shown to act as myb-responsive  repressor ele- 
ments. Both the mouse and human c-f  ms promoters contain 
repeated  weak myb binding sites concentrated  in the same 
60-80-bp region. These sites are annotated on Fig. 2 A  and 
aligned with the MBSII sequence in Fig. 2 B. The sequences 
appear conserved between species and in one region overlap 
a perfectly  conserved AP1  site (TGACTCA). 
ets Family Transc@tion Factors Can trans-Activate the c-f  ms 
Promot~  To confirm evidence of trans-activation of the mouse 
c-f  ms promoter by ets factors (14), we cotransfected  the human 
c-f  ms reporters represented  in Table I with expression vectors 
for ets-1, ets-2, or PEA3. The same general outcome was ob- 
tained for all promoter reporters  tested, but only the results 
for the  -430 proximal promoter construct are displayed in 
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AAGGGCAGAT 
CAGGGTAAAG 
C  .......  TC 
CTTTGGGATC 
API 
GdTCCTGACT 
GCTACT~C~ 
TGTCCTTAGA 
ACCCCTTGAA 
AGGATCAGTT 
AAGCTCAGGC 
GAGAAA..GG TATG.AAGAA TGTAGGATAA CCTGACCTCT 
AAAAAATAAA TATGTCACAA TATCATGCAA CCTAACTTCT 
AGCCAGGCTC A.CTG~GAGAC  TCTTATTTAT 
TGCCAGAGCC ACCTGATCAC TCTG.AAGAC CCTCATTTGT 
AP1  PU-e~ 
CAGAGGCTG. CTGCTCTTGG  GATATGACTC  CTCTCCTAAG 
AACGGTCTGG CTGCTCTTGG .ACATGTCTC TTCTCCCAGG 
PU-ets 
GGTGGTTTCC TAAGTCTCTC AAACTCCATC ATCTCCCTTC 
GATGGCTTTA  GAAGGGCCCC  AAACTTAGCT  AGCTCCCCCC 
I"  pu-,~ 
GAGCCTGGCC CCAGATTCTG CCTCTTCCTC TGGTGTGTGG 
TGGCCCTGCC CCAGACTGCG ACCCCTCCCT CTTGGGTTCA 
TGTGTGTGTG TGTGTGTGTG TGTGTGTGTG TGTGTATGTG TGTGTGCTTT 
AG  ...........................................  GCTTT 
FU-e~  PU-e~ 
GTTTTCTTCT AGAGACCCAA TATTTCCAAA TTCTGTAGTT CCCTTTCAGG 
GTTTTCTTCT AAAGACCCAA GATTTCCAAA CTCTGTGGTT GCCTTGCCTA 
PU-ets 
CAACCTAAAA AAAAAAAAAA  AAAAAAAAAA  GGGGAAGAGG .......... 
GCT~AA~G~.$ ~zAA~AGAGG ATCAGC~AA GGAGGAGGAA GAGGAAAACA 
........  AG CCAGTGC.~AC AGACAGGAAC GTGTTCATC. TGTTCCCG.T 
AGACAAACAG CCAGTGCAGA GGAGAGGAAC G~_~TCCAG TGT.CCCGAT 
CCTCACAGAA  eTAGeAGeTG  GGA~CCCCG'r  GCeCAGCCGA  eTCTCc~cF~c  r'~ 
CCCAGCGGAG CTAGTAGCTG  AGAGCTCTGT  TCCTGGGCAC  CTTGCAGCCC 
I-" F"  F" 
TGCATCGGCT CACGCTATCC CCTG.GAGGC T~-~GAG 
TGCACCTGCC TGCCACTTCC CCACCGAGGC ~GC 
YAaCnGnH  myb* 
ACACCCTAACTGACACACA  ~SI 
GCTGACTAATTGAGATGCA  MBSII 
TAGGATAACCTGACCTCTC  -470(m) 
CCAGGCTCACTGCTCATCT  -440(m) 
ACTGCTCATCTGGGAGACT  -430(m) 
TTTATGCTCCTGACTCAGA  -408(m) 
ATCCCAGAGCAGCCTCTGA  -390r(m) 
CAGAGCCACCTGATCACTC  -420(h) 
TTTGTGCTACTGACTAACG  -390(h) 
ACTGACTAACGGTCTGGCT  -383(h) 
TGTCCAGAGCAGCCAGACC  -360r(h) 
Figure  2.  Sequences  of the human and mouse c-f  ms proximal promoters. 
(A) Mouse and human c-f  ms promoter sequences have been reported pre- 
viously (3, 4). Potential PU-ets sites are identified based upon purine-rich 
sequences containing the 5'-GGAA-Y or 5'-GGAT-Y core on either strand. 
Potential weak c-myb sites (43)  are underlined in bold. Arrows indicate 
identified transcription start sites (3,  4). Dotted underline indicates the 
-170 functional PU-box in the human promoter (15). These sequence 
data are available from EMBL/GenBank/DDBJ under accession number 
X14720 (human). (B) Potential weak binding sites for c-myb in the human 
and mouse promoters are aligned with the consensus, strong (MBSI) and 
weak (MBSII) myb sites (43).  Mismatches with the myb consensus are in 
bold. These sequence data are available  from EMBL/GenBank/DDBJ  under 
accession number $62219  (mouse). 
2312  Repression of the c-f  ms Promoter by c-myb Fig. 3 A. The data demonstrated that ets-1 or ets-2 were equally 
effective at trans-activating the c-f  ms proximal promoter. PEA3 
did not activate these reporters, indicating a selectivity in 
factor-promoter interaction. Transactivation occurred in NIH 
3T3 fibroblasts, as well as in RAW264 cells. The average ac- 
tivation was eightfold in the former cell type and about three- 
to fourfold in the latter. The TK or actin promoters were 
not  transactivated by the ets  expression vectors (data  not 
shown).  Hence, the human promoter, like the mouse pro- 
moter, is responsive to ets transcription factors. The respon- 
siveness of the human (15) and mouse (14) promoters to the 
macrophage-specific ets-related factor PU.1 has been described 
previously. Fig. 3 B demonstrates that the human c-f  ms prox- 
imal promoter (-430) is transactivated by coexpression of 
PU.1 in NIH 3T3 cells, as it is in HeLa cells (15). PU.1 in- 
creased proximal promoter activity by six- to sevenfold. 
The alignment of sequences in Fig. 2 A  suggests that the 
ets/PU.l-like  sequences around 150 in the human and  -130 
in the mouse are conserved and might play a role in the tissue 
specificity and ets/PU.1 responsiveness exhibited by this pro- 
moter in the transient assays. To test this possibility, G-residues 
in the consensus sequence necessary for ets factor recognition 
(5, 6) were mutated in the context of the  -430 luciferase 
reporter construct and the activity of the mutated proximal 
promoter was assayed (Fig. 3C, 430-WT vs. 430-M1). The 
experiments revealed that in RAW264 cells the 430-M1 pro- 
moter had 20% of the activity of the 430-wt promoter. The 
point mutations rendered the promoter only twofold more 
active than the TK promoter in RAW264 cells. The abso- 
lute activation of the proximal 430-M1 promoter by c-ets-1 
was largely abrogated, with 10% of the wild-type activity 
remaining.  In terms of fold stimulation over basal  activity 
by c-ets-1  the 430-M1  mutant was stimulated twofold, vs. 
fivefold stimulation of 430-WT.  Therefore, the ets-related 
sequences were critical for the basal activity of this promoter 
in RAW264 cells, and were also necessary for eflficient trans- 
activation by c-ets-I. 
Because PU.1 is already expressed in RAW264 cells, and 
overexpression causes repression (14) the effect of the muta- 
tion of the  -  150 element was tested in NIH 3T3 cells (Fig. 
3 B). The mutation caused a lesser reduction in basal activity 
in NIH 3T3 cells than in RAW264 cells (40% decrease in 
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Figure 3.  Activation  of the c-f  ms proximal  promoter  by c-eta.l, c-ets-2, 
and PU.1 and the role of the putative - 15- response  element.  (.4) CSFR- 
430 reporter  was cotransfected  with expression  vectors  for ets-factors  into 
either  NIH 3T3 cells  or RAW 264 cells, as indicated,  by calcium  phosphate- 
mediated transfection  (NIH 3T3 cells)  or electroporation  (RAW264  cells). 
Rous sarcoma virus-secreted  alkaline phosphatase (RSV-SEAP) was in- 
cluded as internal control. For the latter, 20/~g of DNA was added per 
experiment,  consisting  of 15/~g of reporter, 1/zg of transactivator  expres- 
sion vector, 1 ~g of RSV-SEAP, and 3/zg of  carrier  plasmid vector  DNA. 
The luciferase  activity  was assayed  48 h posttransfection.  (B) 10/~g  of  CSFR- 
430 (WT) or a plasmid mutated  in the - 150 PU-ets site (CSFR-430-M1) 
was cotransfected  into NIH 3T3 cells  with 1/zg of either  PU.l-expression 
plasmid PU-pECE  or the host  plasmid (pECE)  by dectroporation  (Materials 
and Methods). Luciferase  activity  was assayed after 24 h. (C) 20/~g of 
reporter plasmids containing either  wild-type  CSFR-430 or the mutated 
CSFR-430 (M1) promoter  was transfected  into RAW264 cells with 1/~g 
of either  parent plasmid (basal) or the c-ets-1 expression  vector  (open bars) 
1/~g of RSV-SEAP, and 3/zg of carrier plasmid. Luciferase  activity  was 
assayed after  48 h. The above  experiments  are the average  of three separate 
experiments,  each  performed  in duplicate  and the error  bars indicate  the SD. 
2313  Reddy  et al. activity vs. 80%). Additionally, the 430-M1 reporter displayed 
a 60% reduction in PU.1 responsiveness, to 2.5-fold stimula- 
tion over  the basal activity. 
EMSA  of Nuclear Proteins  That Interact with the  -150 Ele- 
ment of  the Human c  fms Promot~  The expression vector used 
for c-ets-2  placed an influenza virus-derived epitope tag at 
the NH2 terminus of the transcription factor (39),  thus al- 
lowing exogenous c-ets-2 to be distinguished from the en- 
dogenous protein. The epitope-tagged c-ets-2 was employed 
to detect interactions of this protein with sequences in the 
CSF-1R proximal promoter. In EMSA using the wild-type 
ets-oligonucleotide,  an increase in a specific DNA binding 
complex was observed in extracts that contained overexpressed 
c-ets-2 (Fig. 4 A, lane 3 vs. lane 1, open arrow). Competition 
with excess homologous oligonucleotide abolished the for- 
mation of this complex (Fig. 4 A, lane 4),  while competi- 
tion with the oligonucleotide containing point mutations in 
the ets-related sites (see Materials and Methods) did not affect 
complex formation (Fig.  4 A, lanes 5 and 6).  Inclusion of 
monoclonal antibody 12CA5-F,  specific to the epitope-tag 
(39) that marked the exogenous c-ets-2, in the EMSA resulted 
in a supershift of this complex (Fig. 4 B, lanes  8-10,  closed 
arrow). Increasing the amount of specific  antibody in the EMSA 
caused an increase in the supershifted complex, while having 
no effect on the endogenous c-ets-2  complex formed when 
mock-transfected extracts were used (Fig. 4 A, lanes 2-4). 
Monoclonal antibodies directed against the yeast transacti- 
vator gal4 or c-myb had no effect on complex formation (Fig. 
4 A, lanes 11 and 12, respectively). A complex with identical 
mobility to the ets-2 complex shown in Fig. 4 was also found 
in nuclear extracts from RAW 264 cells, which express ets-2 
mRNA (data not shown). 
Zhang et al. (15) suggested that PU.1  could not bind to 
the - 150 c-f  ms ets-like sequence we have studied. Fig. 5 com- 
pares the mobility of RAW264 nuclear proteins that bind 
this sequence to recombinant PU.1 expressed in E. coli. One 
RAW264 nuclear protein bound to the wild-type, but not 
mutant M1 sequence. This protein comigrated with recom- 
binant PU.1, which also bound specifically to the c-f  ms se- 
quence, and with a protein that binds the SV40 PU-box rec- 
ognition site for PU.1 (Fig. 5, lanes 2 and 3, compared with 
lanes 6 and 7). The identity of PU.1 as the only nuclear pro- 
tein in RAW264 cells that binds the SV40 PU box has previ- 
ously been confirmed by antibody supershift and the pattern 
of partial protease cleavage (14). Hence, both native and recom- 
binant PU.1 are able to bind specifically  the - 150 c-f  ms purine- 
rich sequence and the mutations that reduce activity of the 
promoter (Fig.  3 B)  abolish PU.1 binding (Fig.  5, lanes 4 
and 5). 
c  fms mRNA Expression and Promoter Activity Increase during 
M1  Cell Differentiation.  In view of the apparent presence of 
candidate c-myb repressor sites in the mouse and human c-f  ms 
promoters (Fig. 2 A  and B), we investigated the activity of 
the promoters in the M1 murine myeloid leukemia line. This 
line undergoes macrophage differentiation in response to LIF 
in parallel with a decline in c-myb mKNA expression  (45). 
Fig. 6 shows the time course of induction of c-f  ms mKNA 
in M1 cells undergoing differentiation in response  to LIF. 
c-f  ms mRNA first became detectable after 2 d of LIF treat- 
ment, and maximal expression  occurred by day 3 after LIF 
treatment. A similar time course of induction was reported 
previously for other macrophage-specific  genes such as lyso- 
zyme (45). The level of c-myb mRNA actually increased in 
control cells during the time course of the experiment, prob- 
ably reflecting an increase in growth rate as the cells were 
diluted. Within 24 h of addition of LIF, c-myb mRNA levels 
were decreased  and became undetectable after 48  h of LIF 
treatment (Fig. 6). Thus, the disappearance of c-myb mKNA 
correlated with the expression  of c-f  ms mRNA. 
When the 3.5-kb murine c-f  ms promoter was assayed by 
transient  transfection  in  M1  cells,  the  activity was  not 
significantly greater than that of the promoterless  pGL2-basic 
Figure  4.  Interaction  of c-ets-2 
with the purine-rich sites in the 
CSF-1R proximal promoter. (A) 
Whole cell extracts of the COS-7 
cells transfected  with  pCGN (empty 
expression vector, lanes I and 2) or 
pCGN-c-ets-2 (epitope-tag vector, 
lanes 3-6) were incubated with a 
double-stranded 32P-labded probe 
containing  the ets-related  sequences 
highlighted  in Fig. 2  A. In the reac- 
tions loaded into lanes 2 and 4, 
a 20-fold  molar excess of homolo- 
gous oligonucleotide  was included, 
whereas for those  in lanes 5 and 6, 
a 20- or 40-fold  molar excess, respectively,  of the corresponding  mutated  oligonucleotide  (see Materials  and Methods)  were included. The open arrow 
indicates the position of the specific  c-ets-2 complex. (B) Whole cell extracts of the COS-7 cells transfected  with pCGN (empty  expression  vector, lanes 
1--6) or pCGN-c-ets-2 (epitope-tag vector, lanes 7-12) were incubated with a double-stranded  32p-labded probe containing  the ets-related sequences 
highlighted  in Fig. 1 B (see Materials  and Methods). Lanes 1 and 7 had no addition.  Lanes  3-5 and 8-10 had increasing  amounts  of the affinity-purified 
monoclonal  antibody  specific  to the epitope tag, 12CA5-F, added  (0.25 #g, 0.5 #g, 1 #g, respectively).  Lanes  5 and 11 had 2/zg ofa monoclonal  antibody 
specific for the yeast transactivator  gal4 added (a gift from Ivan Sadowski, University  of British Columbia,  Vancouver, Canada) whereas lanes 6 and 
12 had 2 #g of monocional  antibody  directed against  mouse  c-myb (type  I, UBI) added. The extracts were preincubated  for 10 rain with monoclonal 
antibodies before addition  of the probe. The open arrow indicates  the position of the specific  c-as-2/DNA  complex  and the closed  arrow represents the 
super-shifred c-ets-2/DNA complex. 
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Figure 5.  The binding of native and recombinant PU.1 to the  -150 
PU-ets site of the human c-f  ms promoter. Electrophoretic mobility shift 
analysis was conducted as described (14). 2 #g of nuclear protein from 
RAW264 cells (lanes  2, 4, and 6) or mouse PU.1 expressed  in E. coli  (lanes 
3, 5, and 7) was incubated with radiolabeled  c-fras - 150 oligonucleotide 
(lanes 2 and 3), MT-1 mutated oligonucleotide (lanes 4 and 5) or SV40 
PU-box (14) together with 1 #g of poly-d(I,C). Arrow  A marks the mo- 
bility of  recombinant PU.1 (which contains the FLAG  epitope tag); Arrow 
B marks the mobility of native PU.1. 
negative control plasmid,  a relative activity even lower than 
in NIH 3T3 cells. Differentiation of the cells in LIF led to 
a  10-20-fold induction of c-f  ms promoter activity (Fig.  7). 
The activity of other control promoters tested also increased, 
though only by two- to threefold, perhaps reflecting altera- 
tions in transfection efftciency. The results are consistent with 
the data indicating that the c-f  ms promoter contains elements 
that can direct monocyte/macrophage-specific expression of 
reporter genes,  and  that c-myb  may play some role in  this 
regulation. 
The latter possibility was tested directly in RAW264 cells 
(Fig.  8 A).  Nuclear extracts prepared from RAW264  cells 
had no c-myb DNA binding activity as determined by EMSA, 
and c-myb could not be detected by Western blotting (data 
Figure 6.  Time course of c-f  ms induction and c-myb  repression in M1 
murine myeloid leukaemia cells treated with LIE Northern blot analysis 
was carried out as described  in Materials  and Methods. To control for fluc- 
tuations in c-myb expression  due solely to growth rates and cell density, 
control and LIF-treated cells were harvested on each of the days as indi- 
cated. The same blot was rehybridized for each of the probes. 
Figure 7.  Induction of  c-fras  promoter activity in M1 cells treated with 
LIE M1 cells, or cells differentiated  for 6 d with LIE were transfected 
by electroporation with 10 #g of either promoterless plasmid (pGbB), 
pGL2-3.5fms (3500 c-f  ms murine promoter), pGbP (SV40 minimal early 
promoter) or pGL2-~r (actin)  hciferase  reporters  as indicated. I.aciferase 
activity was assayed  after 24 h. The number shown is the average  of three 
experiments varying by <15%  from the mean, the actual luciferase  ac- 
tivity is presented above each column. 
not shown). Transient expression of exogenous c-myb led to 
a 70-80%  reduction of either the  -5,000 or  -430 human 
c-f  ms promoter activity (Fig.  8 A).  Further,  neither v-myb 
or a COOH-terminal  truncated version of c-myb that lacks 
the last 199 amino acid residues were able to mimic this repres- 
sion. A c-f  ms promoter reporter truncated at position  -  367, 
just  downstream of the candidate c-myb binding  sites (Fig. 
2 A), was not affected by expression ofc-myb proteins. EMSA 
and supershift assays demonstrated that the perfect c-myb con- 
sensus sequence located at position  -383 in the human pro- 
moter (see Fig.  2 B) was recognized by recombinant c-myb 
protein  (data  not  shown),  c-myb was  equally effective as  a 
repressor of the full-length 3.5-kb mouse promoter, causing 
a 70%  reduction in promoter activity (Fig.  8 B).  Deletion 
of the proximal murine promoter to 0.3 kb, which again re- 
moves the putative c-myb sites, abolished the repression (Fig. 
8 B). The repressive action of c-myb was specific to the fins 
promoter. When a reporter containing 5 myb-consensus sites 
upstream ofa TK promoter (20) was tested, v-myb and both 
c-myb constructs trans-activated  expression, and, as expected 
(37,  38),  v-myb  or  truncated  c-myb  were  stronger  trans- 
activators  than  full-length  c-myb  (Fig.  8 A). 
The relationship between c-ets-1 or c-ets-2 activation and 
c-myb repression was tested using the 430-WT  human fins 
promoter (Fig.  8  C).  c-myb  expression was  able  to repress 
ets-factor  stimulation of c-f  ms proximal promoter activity in 
RAW264 cells. As above, COOH-terminal truncated c-myb 
(Fig.  8  C)  or  v-myb  (data  not  shown)  were  ineffective 
repressors.  When the effect of c-myb on the c-f  ms proximal 
promoter was tested in NIH 3T3 cells (Fig. 8 D), there was 
no repression of the basal promoter activity of the CSFR- 
5000 reporter, but instead slightly (2.5-fold) stimulated pro- 
moter activity. As demonstrated above, c-ets-2 transactivated 
the proximal promoter in NIH 3T3 cells. In contrast to the 
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Figure 8.  Repression of the c-f  ms promoter by c-myb. (A) 10/xg of CSFR-5000, CSFR-430, CSFR-367 human c-f  ms promoter, or artificial myb-TK 
(5 myb consensus sites, 20) reporters as indicated, were transfected into RAW264 cells by electroporation  in the absence or the presence of 2/zg of 
expression vectors encoding full-length c-myb, COOH-terminal truncated c-myb or v-myb (stippled bars). The results are the average of three independent 
experiments performed in duplicate (+_  SD). (B) 10 #g of pGL2-O.3fms or pGL2-3.Sfms (proximal or full-length routine c-f  ms promoters) luciferase 
reporters, together with 2 #g of control plasmid or myb expression plasmid as indicated, were transfected into RAW264 cells by electroporation.  Lu- 
ciferase activity was assayed after 48 h. Results are the average of three experiments (+_  SD). (C) CSFR-430 human c-f  ms luciferase reporter  (10/xg) 
was transfected into RAW 264 cells with 1 #g of expression vectors for c-ets-1 or c-ets-2, together with control plasmid, full-length c-myb or COOH- 
terminal truncated c-myb expression plasmids as indicated.  The results are the average of three independent experiments performed in duplicate (+ 
SD). (D) NIH 3T3 cells were transfected by calcium phosphate precipitation with the human c-f  ms reporter CSFR-5000 with or without full-length 
c-myb expression vector, c-ets-1 expression vector or both as indicated. The results are the average  of three independent experiments performed in duplicate 
(_+  SD). 
results in RAW264 cells, a combination of c-ets-2 and c-myb 
was not significantly different than c-ets-2  alone (Fig.  8 D). 
The same results were obtained in the K562 cell line (data 
not shown). These results demonstrate a cell-type specificity 
for c-rnyb  action. 
Discussion 
The data presented here indicate that sequences in the 450-bp 
flanking the c-f  ms start codon of both the mouse and human 
c-f  ms  genes  can  direct  macrophage-specific  expression  of 
reporter genes. This conclusion is not incompatible with a 
previous study on the mouse promoter  that  demonstrated 
that attenuation of transcription was a crucial point of regu- 
lation (4). The nonmacrophage cell lines used in that study 
were all tumorigenic.  We have shown subsequently that the 
murine c-f  ms promoter is activated by serum and by malig- 
nant transformation (Hume, D. A., unpublished observations). 
Hence, the choice of controls is important  to identification 
of tissue-specific cis-acting elements by transient transfection. 
Ultimately,  the elements required for specific expression of 
c-f  ms will need to be delineated in  transgenic  mice. 
In studying the role of purine-rich ets-like sequences as cis- 
acting elements in the human c-f  ms promoter, we have con- 
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of that previously studied by Zhang et al. (15) around  -  170. 
This element is apparently conserved in the mouse promoter 
(Fig.  2 A). Mutation of the ets-related  sites at around posi- 
tion  -150 led to a substantial reduction of the c-f  ms prox- 
imal promoter activity, demonstrating that these sequences 
are necessary for maximal transcription in RAW264 macro- 
phages.  Either c-ets-1 or c-ets-2 directly activated the promoter 
via these sequences in a cell-type independent  manner  and 
an epitope-tagged form of c-ets-2 recognized the critical se- 
quences. Whereas the expression of c-ets-1 is thought  to be 
lymphocyte-specific (6), c-ets-2 is expressed in macrophages 
(14) and is a candidate as one factor necessary for c-f  ms prox- 
imal promoter activity. PU.1 also binds the  -150 element, 
in contrast to the findings of Zhang et al. (15) who reported 
that this site was not recognized by PU.1. Further, mutation 
of the  -  150 downstream element reduced transactivation by 
PU.1 in NIH 3T3 cells. We conclude that multiple members 
of the ets family can interact with  the  -150 element,  and 
that the -  170 PU/ets site (15) is not the only such functional 
element in the human c-fins promoter.  Both the  -150 ele- 
ment described here and the - 170 element appear to be neces- 
sary, but not sufficient, for human c-f  ms promoter specificity. 
PU.1 and c-ets-2 probably mediate their effects on c-f  ms 
gene expression by interacting  with other proteins.  In our 
hands,  a PU-box multimer  has no effect on the activity of 
a basal promoter when tested in RAW264 cells (Ross, I. L., 
C. J.  K.  Barnett,  and D.  A.  Hume,  unpublished  observa- 
tions). Similarly PU.1 expression in B cells did not transacti- 
vate a PU-box multimer from the IgkY enhancer unless the 
adjacent binding site for another factor, NF-EM5 was included 
(9).  PU.1 binds specifically  to the TATA-binding protein in 
vitro (46).  Zhang et al. have previously suggested that PU.1 
may recruit TATA binding protein to TATA-less promoters 
such as that of c-f  ms (15). The -150(h)/-130(m) PU.1 binding 
site we have studied is placed rather more appropriately than 
the more distal - 170 for such a function. Like a typical TATA 
box, it is around 30-40 bp upstream relative to the major 
transcription  start sites of the mouse and human,  and unlike 
the  -  170 site appears  to be conserved between the two spe- 
cies  (Fig.  2 A). 
Our  studies  suggest  that c-f  ms is  subject to negative as 
well as positive regulation during myeloid differentiation.  The 
repression of the human c-f  ms promoter by c-myb was medi- 
ated by sequences between -430 and  -367, which contains 
multiple c-rayb sites conserved between mouse and human 
promoters. The less refined deletion of the mouse promoter 
supports the idea that the elements are conserved function- 
ally, in that the 0.3-kb mouse promoter was c-myb unrespon- 
sive. Full-length c-myb was a repressor of the c-f  ms proximal 
promoter, but neither a COOH-terminal  truncated version 
of c-myb nor v-myb, which also lacked the COOH-terminal 
domain,  functioned as an efficient repressor.  The COOH- 
terminal domain has been shown to be a c/s-acting negative 
element that blocks c-myb tram-activation  and transforming 
activity (36, 37). Our results suggest an additional function 
for this domain as a site involved in the tram-repressive  ac- 
tivity seen in RAW264 cells. This conclusion is quite different 
from the results of Sakura et al. (44). In their studies of the 
myb responsive elements of SV40,  the weaker MBSII sites 
functioned only as c/s-acting repressor elements in a cell-type 
independent manner and the COOH terminus of c-myb was 
not required  for repression. 
When activating transcription, c-myb action is context de- 
pendent hinging  on interactions  with other transactivators 
(31-34). The repression of the c-f  ms proximal promoter by 
c-myb is also context dependent, since when assayed with a 
heterologous promoter the human c-myb-responsive element 
can function as an enhancer (data not shown). Additionally, 
c-myb repression of the human c-f  ms proximal promoter did 
not occur in NIH 3T3 cells. Thus, interaction(s)  with dis- 
tinct transactivators are probably crucial for repression of the 
c-f  ms promoter by c-myb as well. Since c-myb is already known 
to interact with ets factors in transactivation (32) and c-myb 
blocked activation of the c-f  ms proximal promoter by c-ets-I 
or c-ets-2 in RAW264 cells, ets factors present attractive  targets 
for the negative action of c-rayb. In this context, the parallel 
between myb and PU.1 is of some interest. PU.1 is the product 
of the Spi-1 protooncogene, which was identified as a major 
site of integration  of spleen focus forming virus (47).  Like 
c-rnyb (48),  PU.1 can prevent erythropoietic differentiation 
(47). The possibility that myb can interact with PU.1 is worthy 
of further  consideration. 
Knockout experiments in transgenic mice demonstrate the 
critical role of the c-myb protooncogene product in the ex- 
pansion and maintenance of hematopoietic stem cells (22). 
Our results suggest that, in addition to activating genes re- 
quired for stem-cell growth and survival, a significant effect 
of c-myb during the early stages of hematopoiesis may be to 
repress the expression of key regulatory genes necessary for 
the terminal stages of differentiation, such as c-f  ms. The tran- 
scriptional repressor activity of c-myb may provide a check- 
point ensuring that precursor cells cannot prematurely enter 
terminal differentiation pathways. The loss of this capacity 
from oncogenic forms of myb may contribute to their trans- 
forming potential. 
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